- Home
- SHLS vs SPRY Comparison
SHLS vs SPRY Comparison
Compare SHLS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | SPRY |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 946.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SHLS | SPRY |
|---|---|---|
| Price | $8.11 | $9.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $9.42 | ★ $31.25 |
| AVG Volume (30 Days) | ★ 4.1M | 2.2M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $433,993,000.00 | $142,772,000.00 |
| Revenue This Year | $20.62 | N/A |
| Revenue Next Year | $18.88 | $124.59 |
| P/E Ratio | $42.50 | ★ N/A |
| Revenue Growth | 2.68 | ★ 5459.66 |
| 52 Week Low | $2.71 | $6.66 |
| 52 Week High | $11.36 | $18.90 |
Technical Indicators
Market Signals| Indicator | SHLS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 60.08 |
| Support Level | $7.68 | $9.02 |
| Resistance Level | $8.39 | $9.76 |
| Average True Range (ATR) | 0.44 | 0.62 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 69.60 | 89.59 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.